Associate Editor, Pain
Editorial Board, Journal of Pain
Editorial Board, Current Pain and Headache Reports
Professional Advisory Board, American Chronic Pain Association
Neuropathic Pain Advisory Council, Neuropathy Association
Zoster Working Group, Centers for Disease Control and Prevention
Special Government Employee, Food and Drug Administration
Director, Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION), a public-private partnership with the Food and Drug Administration (http://www.acttion.org)
Methodologic aspects of analgesic clinical trials
Treatment and prevention of chronic pain
My current research focuses on methodologic aspects of acute and chronic pain clinical trials, especially identifying factors that increase the assay sensitivity of a trial to detect differences between an active and a control or comparison treatment. With funding from the US Food and Drug Administration (FDA), we are examining in large databases of acute and chronic pain trials the relationships between study methodologic features and study outcomes and placebo group responses, as well as comparing the responsiveness to treatment effects of different primary and secondary outcome measures. These studies and other efforts to improve the efficiency and informativeness of analgesic clinical trials are being conducted under the auspices of the Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks (ACTTION) public-private partnership with the FDA, of which I serve as director.
In addition, in collaboration with Dennis Turk at the University of Washington, we are currently conducting a randomized clinical trial of tramadol, cognitive-behavior therapy, and health education alone and in combination for the treatment of fibromyalgia.
I have also been very interested in the identification of risk factors for the development of chronic neuropathic pain. One of our major results has been that patients with greater acute pain are more likely to develop chronic pain. This suggests that attenuating acute pain might prevent chronic pain, and an additional focus of my research has involved developing approaches to test this hypothesis.
1R01 AR059102-01A (9/1/11-7/31/16)
NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases
Combined behavioral and analgesic trial for fibromyalgia (COMBAT-FM)
Role: Principal Investigator
U01 FD004187-01 (9/15/11-8/31/16)
Food and Drug Administration
Analgesic clinical trial innovations, opportunities, and networks (ACTION)
Role: Principal Investigator
T32 NS007338 (7/1/90-6/30/15)
NIH/National Institute of Neurological Disorders and Stroke
Experimental therapeutics of neurological disease
2014 Aug 11
Hunsinger M, Smith SM, Rothstein D, McKeown A, Parkhurst M, Hertz S, Katz NP, Lin AH, McDermott MP, Rappaport BA, Turk DC, Dworkin RH. "Adverse event reporting in non-pharmacologic, non-interventional pain clinical trials: ACTTION systematic review." Pain.. 2014 Aug 11; Epub 2014 Aug 11.
Zimering JH, Williams MR, Eiras ME, Fallon BA, Logigian EL, Dworkin RH. "Acute and chronic pain associated with Lyme borreliosis: Clinical characteristics and pathophysiologic mechanisms." Pain.. 2014 Aug; 155(8):1435-1438. Epub 2014 Apr 24.
Farrar JT, Troxel AB, Haynes K, Gilron I, Kerns RD, Katz NP, Rappaport BA, Rowbotham MC, Tierney AM, Turk DC, Dworkin RH. "Effect of variability in the 7-day baseline pain diary on the assay sensitivity of neuropathic pain randomized clinical trials: An ACTTION study." Pain.. 2014 Aug; 155(8):1622-31. Epub 2014 May 14.
2014 Jul 24
Dworkin RH, McDermott MP. "Back to the future: The need to resolve analgesic efficacy in human immunodeficiency virus neuropathy." Pain.. 2014 Jul 24; Epub 2014 Jul 24.
Munch T, Dufka FL, Greene K, Smith SM, Dworkin RH, Rowbotham MC. "RReACT goes global: perils and pitfalls of constructing a global open-access database of registered analgesic clinical trials and trial results." Pain.. 2014 Jul; 155(7):1313-7. Epub 2014 Apr 13.